title: Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?
authors.forename: Keisuke
authors.initials: K
authors.lastname: Miyazawa
authors.forename: Jiroh
authors.initials: J
authors.lastname: Nishimaki
authors.forename: Tomoko
authors.initials: T
authors.lastname: Katagiri
authors.forename: Goro
authors.initials: G
authors.lastname: Sashida
authors.forename: Nahoko
authors.initials: N
authors.lastname: Shoji
authors.forename: Ken
authors.initials: K
authors.lastname: Kawakubo
authors.forename: Akitaka
authors.initials: A
authors.lastname: Suzuki
authors.forename: Takashi
authors.initials: T
authors.lastname: Shimamoto
authors.forename: Akihiko
authors.initials: A
authors.lastname: Gotoh
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Kuriyama
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Ito
authors.forename: Tetsuzo
authors.initials: T
authors.lastname: Tauchi
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kawanishi
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Kimura
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ohyashiki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate